In our blog series with Deloitte, we have written extensively about the benefits of using Real World Data (RWD) to enhance clinical trials and accelerate research into new therapies for a variety of conditions.
This year we have covered:
➡ RCTs and RWD: What are they and how do they complement each other in cancer research?
➡ What Makes a fit-for-purpose database for clinical oncology research?
➡ Building a better ECA: 5 steps for submitting an ECA to regulators
➡ How to identify and address data biases when creating an ECA
➡ How to use real-world clinicogenomic data to fuel drug development
